Roche: FDA approves drug combo Venclexta plus Gazyva for previously untreated chronic lymphocytic leukemia




  • In Business
  • 2019-05-16 05:43:19Z
  • By Reuters
Swiss drugmaker Roche
Swiss drugmaker Roche's logo is seen at their headquarters in Basel  

ZURICH (Reuters) - Roche said on Thursday that the U.S. Food and Drug Administration had approved a treatment using its drugs Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukemia.

"Venclexta plus Gazyva is the only chemotherapy-free option of fixed duration that provides durable responses to help people live longer without progression of their disease, compared to a standard-of-care," Roche's Chief Medical Officer Sandra Horning said in a statement.

(Reporting by Brenna Hughes Neghaiwi; Editing by Michelle Martin)

COMMENTS

More Related News

Does Sunscreen Expire?
Does Sunscreen Expire?

The unofficial start of summer, Memorial Day, isn't too far off. And it's around this time that many people start taking stock of their sunscreen supply. Do you need to buy a new bottle, or will ...

Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs

FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business

facebook
Hit "Like"
Don't miss any important news
Thanks, you don't need to show me this anymore.